EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access

Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials

Emanuela Palmerini iD, Cristina Meazza, Angela Tamburini, Catalina Márquez-Vega iD, Gianni Bisogno iD, Franca Fagioli iD, Virginia Ferraresi, Giuseppe Maria Milano, Luca Coccoli iD, Alba Rubio-San-Simón iD, Oscar Gallego iD, María Esther Llinares Riestra und 19 weitere

Journal of Clinical Oncology · 2025-10 · 43 (28) · 3113-3122

DOI: 10.1200/jco-25-00210 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Clinical Oncology, 2025-10. Verfasst von Emanuela Palmerini und 30 weiteren Autor:innen. Beteiligte Einrichtung: Osteoncology, Bone and Soft Tissue Sarcomas, and Innovative Therapies Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy. Hauptthemen laut MEDLINE: Osteosarcoma, Bone Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Acetylmuramyl-Alanyl-Isoglutamine. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Outcome of patients with localized osteosarcoma is challenging. The role of mifamurtide is still a matter of debate. Two prospective trials were carried out in Italy (ISG/OS-2) and Spain (GEIS-33) with mifamurtide in ABCB1/P-glycoprotein (Pgp)–positive patients. PATIENTS AND METHODS Patients age ≤40 years with localized extremity high-grade osteosarcoma were eligible. Analysis of Pgp expression from diagnostic biopsy was centralized. Patients received two cycles of preoperative methotrexate, doxorubicin, and cisplatinum (MAP) before surgery. Postoperatively, in case of Pgp overexpression (Pgp-positive), mifamurtide was added, combined with doxorubicin (one cycle) and four consecutive cycles of high-dose ifosfamide (HDIFO) for patients with poor histologic response, or with MAP in case of good response. Patients who were Pgp-negative received MAP postoperatively. We present the merged analysis of ISG/OS-2 and GEIS-33 trial, an observational study with same inclusion criteria and treatment of ISG/OS-2. The primary endpoint was 5-year event-free survival (EFS) according to the use of mifamurtide. Secondary endpoint was overall survival (OS). RESULTS From March 2013 to April 2018, 398 patients were analyzed. The median age was 14 years (range, 4-40), male/female: 238/160 (1.48/1.0); 211 of 398 (53%) tumors were Pgp-positive, and 204 of 398 (51.3%) patients received mifamurtide. With a median follow-up of 70 months (IQR, 49-90 months), the 5-year EFS and OS were 65.2% (95% CI, 60.1 to 69.8) and 74.8% (95% CI, 69.8 to 79.0), respectively, with superior EFS for patients undergoing mifamurtide and chemotherapy as compared with EFS of patients undergoing chemotherapy alone (5-year EFS 71.4% v 58.3%; P = .0139) not confirmed at multivariable analysis ( P = .0593). CONCLUSION In this merged analysis with a risk-adapted strategy for nonmetastatic osteosarcoma, the group with unfavorable prognoses, identified by Pgp expression, performed well when mifamurtide, combined with HDIFO in case of poor response, was administered after surgery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteosarcomaBone NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAcetylmuramyl-Alanyl-IsoglutamineHumansMaleFemaleAdultAdolescentYoung AdultChildDoxorubicinProspective StudiesItalySpainIfosfamideNeoplasm GradingCisplatinMethotrexatePhosphatidylethanolamines

Substanzen

mifamurtideAcetylmuramyl-Alanyl-IsoglutamineDoxorubicinIfosfamideCisplatinMethotrexatePhosphatidylethanolamines

Autor:innen und Institutionen

  • Osteoncology, Bone and Soft Tissue Sarcomas, and Innovative Therapies Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
  • Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL.
  • Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Department of Pediatric Onco-Hematology, AOU Meyer-IRCCS, Florence, Italy.
  • Pediatric Oncology Unit, Hospital Infantil Universitario Virgen del Rocío, Sevilla, Spain.
  • Department of Women's and Children's Health, University of Padova, Padova, Italy.

ORCID-Profile: Emanuela Palmerini, Catalina Márquez-Vega, Gianni Bisogno, Franca Fagioli, Luca Coccoli, Alba Rubio-San-Simón, Oscar Gallego, Cristina Mata, Elisa Carretta, Marilena Cesari, Anna Paioli, Katia Scotlandi, Sebastian Dorin Asaftei, Marco Gambarotti, Piero Picci, Toni Ibrahim, Javier Martín Broto

Zitieren

APA

Palmerini, E., Meazza, C., Tamburini, A., Márquez-Vega, C., Bisogno, G., Fagioli, F., Ferraresi, V., Milano, G. M., Coccoli, L., Rubio-San-Simón, A., Gallego, O., Llinares Riestra, M. E., Manzitti, C., Mora, J., Vaz-Salgado, M. Á., Luksch, R., Mata, C., Pierini, M., Carretta, E., …, & Broto, J. M. (2025). Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials. Journal of Clinical Oncology, 43(28), 3113-3122. https://doi.org/10.1200/jco-25-00210

Vancouver

Palmerini E, Meazza C, Tamburini A, Márquez-Vega C, Bisogno G, Fagioli F, et al. Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials. Journal of Clinical Oncology. 2025;43(28):3113-3122. doi:10.1200/jco-25-00210

BibTeX
@article{Palmerini2025,
  author = {Palmerini, Emanuela and Meazza, Cristina and Tamburini, Angela and Márquez-Vega, Catalina and Bisogno, Gianni and Fagioli, Franca and Ferraresi, Virginia and Milano, Giuseppe Maria and Coccoli, Luca and Rubio-San-Simón, Alba and Gallego, Oscar and Llinares Riestra, María Esther and Manzitti, Carla and Mora, Jaume and Vaz-Salgado, Mᵃ Ángeles and Luksch, Roberto and Mata, Cristina and Pierini, Michela and Carretta, Elisa and Cesari, Marilena and Paioli, Anna and Marrari, Andrea and Scotlandi, Katia and Serra, Massimo and Asaftei, Sebastian Dorin and Gambarotti, Marco and Picci, Piero and Ferrari, Stefano and Valverde, Claudia and Ibrahim, Toni and Broto, Javier Martín},
  title = {Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {28},
  pages = {3113--3122},
  doi = {10.1200/jco-25-00210}
}
Kostenlos starten →